These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 39009347)

  • 1. A comparison of Polysorbates and Alternative Surfactants for Interfacial Stress Protection and Mitigation of Fatty Acid Particle Formation in the Presence of an Esterase.
    Roy I; Wuchner K; Stahl P; Tran T; Yaragudi N
    J Pharm Sci; 2024 Sep; 113(9):2688-2698. PubMed ID: 39009347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stress-mediated polysorbate 20 degradation and its potential impact on therapeutic proteins.
    Aryal B; Lehtimaki M; Rao VA
    Pharm Res; 2024 Jun; 41(6):1217-1232. PubMed ID: 38740663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Comprehensive Assessment of All-Oleate Polysorbate 80: Free Fatty Acid Particle Formation, Interfacial Protection and Oxidative Degradation.
    Doshi N; Giddings J; Luis L; Wu A; Ritchie K; Liu W; Chan W; Taing R; Chu J; Sreedhara A; Kannan A; Kei P; Shieh I; Graf T; Hu M
    Pharm Res; 2021 Mar; 38(3):531-548. PubMed ID: 33713012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How enzymatic hydrolysis of polysorbate 20 influences colloidal protein stability.
    Glücklich N; Carle S; Diederichs T; Buske J; Mäder K; Garidel P
    Eur J Pharm Sci; 2023 Dec; 191():106597. PubMed ID: 37770006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving Prediction of Free Fatty Acid Particle Formation in Biopharmaceutical Drug Products: Incorporating Ester Distribution during Polysorbate 20 Degradation.
    Doshi N; Martin J; Tomlinson A
    Mol Pharm; 2020 Nov; 17(11):4354-4363. PubMed ID: 32941040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fatty Acids Can Induce the Formation of Proteinaceous Particles in Monoclonal Antibody Formulations.
    Zhang J; He J; Smith KJ
    J Pharm Sci; 2022 Mar; 111(3):655-662. PubMed ID: 34666046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the polysorbate degradation fingerprints and kinetics of lipases - how the activity of polysorbate degrading hydrolases is influenced by the assay and assay conditions.
    Glücklich N; Carle S; Buske J; Mäder K; Garidel P
    Eur J Pharm Sci; 2021 Nov; 166():105980. PubMed ID: 34419573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polysorbate Degradation and Particle Formation in a High Concentration mAb: Formulation Strategies to Minimize Effect of Enzymatic Polysorbate Degradation.
    Roy I; Patel A; Kumar V; Nanda T; Assenberg R; Wuchner K; Amin K
    J Pharm Sci; 2021 Sep; 110(9):3313-3323. PubMed ID: 34077768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Existence of a superior polysorbate fraction in respect to protein stabilization and particle formation?
    Diederichs T; Mittag JJ; Humphrey J; Voss S; Carle S; Buske J; Garidel P
    Int J Pharm; 2023 Mar; 635():122660. PubMed ID: 36740078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Fatty Acid Composition in Polysorbate 80 on the Stability of Therapeutic Protein Formulations.
    Pegues MA; Szczepanek K; Sheikh F; Thacker SG; Aryal B; Ghorab MK; Wolfgang S; Donnelly RP; Verthelyi D; Rao VA
    Pharm Res; 2021 Nov; 38(11):1961-1975. PubMed ID: 34845573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating a Modified High Purity Polysorbate 20 Designed to Reduce the Risk of Free Fatty Acid Particle Formation.
    Doshi N; Ritchie K; Shobha T; Giddings J; Gregoritza K; Taing R; Rumbelow S; Chu J; Tomlinson A; Kannan A; Saggu M; Cai SK; Nicoulin V; Liu W; Russell S; Luis L; Yadav S
    Pharm Res; 2021 Sep; 38(9):1563-1583. PubMed ID: 34495486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complex Micellization Behavior of the Polysorbates Tween 20 and Tween 80.
    Knoch H; Ulbrich MH; Mittag JJ; Buske J; Garidel P; Heerklotz H
    Mol Pharm; 2021 Aug; 18(8):3147-3157. PubMed ID: 34251210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An in-depth examination of fatty acid solubility limits in biotherapeutic protein formulations containing polysorbate 20 and polysorbate 80.
    Glücklich N; Dwivedi M; Carle S; Buske J; Mäder K; Garidel P
    Int J Pharm; 2020 Dec; 591():119934. PubMed ID: 33059015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of Polysorbate Ester Fractions and Implications in Protein Drug Product Stability.
    Tomlinson A; Zarraga IE; Demeule B
    Mol Pharm; 2020 Jul; 17(7):2345-2353. PubMed ID: 32442382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polysorbates versus Hydroxypropyl Beta-Cyclodextrin (HPβCD): Comparative Study on Excipient Stability and Stabilization Benefits on Monoclonal Antibodies.
    Zhang H; Hong S; Tan SSK; Peng T; Goh LYH; Lam KH; Chow KT; Gokhale R
    Molecules; 2022 Oct; 27(19):. PubMed ID: 36235038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, characterization and assessment of suitability of trehalose fatty acid esters as alternatives for polysorbates in protein formulation.
    Schiefelbein L; Keller M; Weissmann F; Luber M; Bracher F; Friess W
    Eur J Pharm Biopharm; 2010 Nov; 76(3):342-50. PubMed ID: 20816956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Super Refined™ Polysorbate 20 With Respect to Polysorbate Degradation, Particle Formation and Protein Stability.
    Doshi N; Fish R; Padilla K; Yadav S
    J Pharm Sci; 2020 Oct; 109(10):2986-2995. PubMed ID: 32679214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Polysorbate 80 Hydrolysis and Oxidation on the Aggregation of a Monoclonal Antibody.
    Larson NR; Wei Y; Prajapati I; Chakraborty A; Peters B; Kalonia C; Hudak S; Choudhary S; Esfandiary R; Dhar P; Schöneich C; Middaugh CR
    J Pharm Sci; 2020 Jan; 109(1):633-639. PubMed ID: 31758949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlled polysorbate 20 hydrolysis - A new approach to assess the impact of polysorbate 20 degradation on biopharmaceutical product quality in shortened time.
    Graf T; Abstiens K; Wedekind F; Elger C; Haindl M; Wurth C; Leiss M
    Eur J Pharm Biopharm; 2020 Jul; 152():318-326. PubMed ID: 32445968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Free fatty acid particles in protein formulations, part 2: contribution of polysorbate raw material.
    Siska CC; Pierini CJ; Lau HR; Latypov RF; Fesinmeyer RM; Litowski JR
    J Pharm Sci; 2015 Feb; 104(2):447-56. PubMed ID: 25196966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.